56.68
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Bio Techne Corp stock is traded at $56.68, with a volume of 2.99M.
It is up +3.54% in the last 24 hours and up +6.68% over the past month.
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. It reports in two segments: protein sciences (about 75% of revenue) and diagnostics and genomics (25%). The protein sciences segment sells reagents and analytical instruments used in life sciences research, including antibodies used in protein analysis. The diagnostics and genomics segment sells diagnostic reagents, molecular diagnostics, and spatial biology products. The United States accounts for about 55% of revenue. The firm also has operations in Europe, the Middle East, and Africa (20% of sales), the UK (5%), and Asia-Pacific (15%), with the rest of the world accounting for the remaining 5%.
See More
Previous Close:
$54.74
Open:
$56.35
24h Volume:
2.99M
Relative Volume:
1.30
Market Cap:
$8.87B
Revenue:
$1.22B
Net Income/Loss:
$81.07M
P/E Ratio:
110.25
EPS:
0.5141
Net Cash Flow:
$223.02M
1W Performance:
+5.92%
1M Performance:
+6.68%
6M Performance:
-5.44%
1Y Performance:
+13.82%
Bio Techne Corp Stock (TECH) Company Profile
Name
Bio Techne Corp
Sector
Industry
Phone
612-379-8854
Address
614 MCKINLEY PL N E, MINNEAPOLIS, MN
Compare TECH vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
|
TECH
Bio Techne Corp
|
56.68 | 8.56B | 1.22B | 81.07M | 223.02M | 0.5141 |
|
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 109.34B | 12.32B | 4.34B | 3.19B | 16.86 |
|
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 74.35B | 14.92B | 4.42B | 3.79B | 41.04 |
|
ARGX
Argen X Se Adr
|
794.70 | 50.44B | 4.16B | 1.29B | 734.26M | 19.58 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 39.78B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.02B | 5.36B | 287.73M | 924.18M | 2.5229 |
Bio Techne Corp Stock (TECH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-03-25 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Aug-21-25 | Upgrade | Citigroup | Neutral → Buy |
| Jul-22-25 | Resumed | Stephens | Overweight |
| Jul-09-25 | Initiated | TD Cowen | Buy |
| May-30-25 | Initiated | Wells Fargo | Overweight |
| Apr-09-25 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
| Mar-18-25 | Initiated | Evercore ISI | Outperform |
| Feb-19-25 | Downgrade | Robert W. Baird | Outperform → Neutral |
| May-22-24 | Downgrade | Citigroup | Buy → Neutral |
| Feb-08-24 | Initiated | Scotiabank | Sector Outperform |
| Feb-02-24 | Downgrade | Stifel | Buy → Hold |
| Dec-07-23 | Initiated | UBS | Buy |
| Aug-28-23 | Initiated | William Blair | Outperform |
| Jan-10-23 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| Dec-14-22 | Initiated | Deutsche Bank | Buy |
| Dec-12-22 | Upgrade | Citigroup | Neutral → Buy |
| Dec-07-22 | Initiated | RBC Capital Mkts | Sector Perform |
| Aug-25-22 | Initiated | Credit Suisse | Outperform |
| Apr-25-22 | Downgrade | Wells Fargo | Equal Weight → Underweight |
| Sep-15-21 | Upgrade | KeyBanc Capital Markets | Sector Weight → Overweight |
| Mar-08-21 | Upgrade | Stephens | Equal-Weight → Overweight |
| Feb-23-21 | Upgrade | Stifel | Hold → Buy |
| Jan-25-21 | Reiterated | The Benchmark Company | Buy |
| Nov-10-20 | Initiated | KeyBanc Capital Markets | Sector Weight |
| Sep-30-20 | Initiated | Atlantic Equities | Overweight |
| Jul-15-20 | Downgrade | Stephens | Overweight → Equal-Weight |
| May-27-20 | Downgrade | Stifel | Buy → Hold |
| May-14-20 | Initiated | The Benchmark Company | Buy |
| Jan-08-20 | Resumed | Stephens | Overweight |
| Jan-08-20 | Initiated | Wells Fargo | Equal Weight |
| Jan-07-20 | Initiated | Citigroup | Neutral |
| Nov-15-19 | Initiated | Stifel | Buy |
| Jul-02-19 | Upgrade | Janney | Neutral → Buy |
| Jan-14-19 | Upgrade | Stephens | Equal-Weight → Overweight |
| Oct-31-18 | Downgrade | Craig Hallum | Buy → Hold |
| Oct-17-18 | Initiated | Goldman | Neutral |
| Jun-15-18 | Initiated | Argus | Buy |
| Jul-13-17 | Initiated | Wells Fargo | Market Perform |
| Feb-09-17 | Initiated | Citigroup | Buy |
| Jan-18-17 | Initiated | Deutsche Bank | Buy |
| Nov-10-16 | Resumed | Leerink Partners | Outperform |
| Jan-21-15 | Reiterated | Robert W. Baird | Outperform |
| Sep-20-13 | Upgrade | Robert W. Baird | Neutral → Outperform |
View All
Bio Techne Corp Stock (TECH) Latest News
Bio-Techne Corp. stock outperforms competitors on strong trading day - MarketWatch
Bio-Techne (TECH) executive nets shares from 794 RSU exercise - Stock Titan
Investors brace for Bio-Techne earnings amid muted outlook By Investing.com - Investing.com Canada
Bio-Techne sets 8 a.m. May 6 webcast for fiscal Q3 results - Stock Titan
Bio-Techne CEO Kim Kelderman to speak at BofA healthcare event - Stock Titan
Bio-Techne to Present at the Bank of America Securities 2026 Global Healthcare Conference - ChartMill
Bio-Techne Corp (TECH) Stock Analysis: Evaluating a 31.36% Potential Upside in the Biotechnology Sector - DirectorsTalk Interviews
MSN Money - MSN
Vanguard Group Inc. Sells 121,495 Shares of Bio-Techne Corp $TECH - MarketBeat
UBS Group AG Raises Position in Bio-Techne Corp $TECH - MarketBeat
Conestoga Capital Advisors LLC Boosts Stock Holdings in Bio-Techne Corp $TECH - MarketBeat
Comerica Bank Increases Position in Bio-Techne Corp $TECH - MarketBeat
Bio-Techne Corp. stock underperforms Thursday when compared to competitors - MSN
Understanding the Setup: (TECH) and Scalable Risk - Stock Traders Daily
Bio-Techne Corp. stock underperforms Wednesday when compared to competitors - MarketWatch
Vanguard (NASDAQ: TECH) holds 7.38% stake — 11.56M shares reported - Stock Titan
Bio-Techne's Q3 Earnings on Deck: What's in Store for the Stock? - Yahoo Finance
Bio-Techne (TECH) Expected to Announce Earnings on Wednesday - MarketBeat
Is There Now An Opportunity In Bio-Techne (TECH) After Recent Share Price Weakness - simplywall.st
Bio-Techne Corp. stock underperforms Tuesday when compared to competitors - MarketWatch
M&T Bank Corp Buys 70,496 Shares of Bio-Techne Corp $TECH - MarketBeat
Bio-Techne Corp (TECH) Stock Analysis: Exploring a 33% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
Impax Asset Management Group plc Invests $11.47 Million in Bio-Techne Corp $TECH - MarketBeat
Bio-Techne (TECH) CEO nets shares after stock option exercise - Stock Titan
[Form 4] BIO-TECHNE Corp Insider Trading Activity - Stock Titan
Bio-Techne Corp. Stock Hits Day Low of $51.13 Amid Price Pressure - Markets Mojo
Bio-Techne to Host Conference Call on May 6, 2026, to Announce Third Quarter Fiscal 2026 Financial Results - Investing News Network
What to expect from Bio-Techne's Q3 2026 earnings report - msn.com
Bio-Techne (NASDAQ:TECH) Stock Price Down 10.3%Time to Sell? - MarketBeat
Bio-Techne Corp. stock outperforms competitors despite losses on the day - MarketWatch
Bio-Techne Corp (TECH) Stock Analysis: Navigating a 22% Potential Upside Amidst Market Dynamics - DirectorsTalk Interviews
Bio-Techne Reorganizes Brand To Link Research Spatial And Diagnostics Workflows - Yahoo Finance
The Technical Signals Behind (TECH) That Institutions Follow - Stock Traders Daily
Revvity, Bio-Techne, Corcept, Supernus Pharmaceuticals, and Phibro Animal Health Shares Skyrocket, What You Need To Know - Yahoo Finance
Arvin Capital Management LP's Bio-Techne Corp(TECH) Holding History - GuruFocus
What to Expect From Bio-Techne's Q3 2026 Earnings Report - Barchart.com
Bio-Techne Introduces Streamlined Brand Architecture to Help Customers Navigate Solutions Faster and With Greater Clarity - Investing News Network
Bio-Techne (TECH) CEO exercises 36,500 options and uses 32,088 shares for taxes - Stock Titan
Bio Techne Corp Stock (TECH) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):